Author

Michael P. Heldebrant

Observed name: Michael P Heldebrant

Observed institutions: University of Siena, BC Cancer Agency, Mayo Clinic, Johns Hopkins University, University of Alabama, Queen's University, Aix-Marseille Université, University of Alabama at Birmingham, Fédération Francophone de Cancérologie Digestive, Johns Hopkins Hospital, UAB Medicine, Canadian Cancer Trials Group, University of Pennsylvania

OpenAlex ID: A5073032602

Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?

2004 · Sharlene Gill, Charles L. Loprinzi, et al. · Journal of Clinical Oncology · 1,021

Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ

2002 · Christina R. Arnt, Mihnea V. Chiorean, et al. · Journal of Biological Chemistry · 263

Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse

2005 · Timothy S Gomez, Michael J Hamann, et al. · Nature Immunology · 151

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

2005 · Ruben A. Mesa, David Loegering, et al. · Blood · 117

Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease

2003 · Eugenia Trushina, Michael P. Heldebrant, et al. · Proceedings of the National Academy of Sciences · 88

Phorbol 12-myristate 13-Acetate Inhibits Death Receptor-mediated Apoptosis in Jurkat Cells by Disrupting Recruitment of Fas-associated Polypeptide with Death Domain

2002 · Xue Wei Meng, Michael P. Heldebrant, et al. · Journal of Biological Chemistry · 77

Heterogeneous Role of Caspase-8 in Fenretinide-Induced Apoptosis in Epithelial Ovarian Carcinoma Cell Lines

2003 · Kimberly R. Kalli, Kathryn E. Devine, et al. · Molecular Pharmacology · 24

Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation

2009 · Xue Wei Meng, Michael P. Heldebrant, et al. · Journal of Biological Chemistry · 15

Determination of Potential Adjuvant Systemic Therapy Benefits for Patients With Resected Cutaneous Melanomas

2002 · Stephan D. Thomé, Charles L. Loprinzi, et al. · Mayo Clinic Proceedings · 10

Works count: 10

Citation count: 1,766

H-index: 9

I10-index: 9